Definitive Contract 75F40118C10186
Award Date
9/18/18
Potential Completion Date
9/25/20
Potential Value
$1.1M
Federal Agency
Food and Drug Administration
Awardee
Cubrc, Inc.
Ultimate Awardee
Not listed
NAICS Category
541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Cost Plus Fixed Fee
Place of Performance
Cheektowaga, NY 14225, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The U.S. Food and Drug Administration (FDA) awarded a $1,155,442.55 Cost Plus Fixed Fee contract to Cubrc, Inc. to conduct research and development on the "Immunogenicity Risk of Peptide Drug Generics and Their Impurities: In Silico and In Vitro Assessment and Validation Methods." The contract, which has a period of performance ending September 27, 2022, was issued under the FDA's Broad Agency Announcement (BAA) solicitation for advanced research and development to support regulatory...
This federal contract award to Cubrc, Inc. (doing business as Cubrc Inc.), a non-profit research and development company, is for the development of universal control peptides to support T-cell assays for immunogenicity. The $2,161,743.00 firm fixed-price contract was awarded by the Food and Drug Administration (FDA), a civilian agency, and has a completion date of September 29, 2026. Cubrc has extensive experience as both a prime contractor and subcontractor on federal research and development...
This is a $20,561.00 firm-fixed price purchase order contract awarded by the Food and Drug Administration (FDA) to Epivax Inc., a for-profit, woman-owned small business in Rhode Island. The contract is for a Human Leukocyte Antigens (HLA) binding study and in-vitro characterization of epitopes. This research supports Epivax's expertise in immunoinformatics and computational biology, including the use of machine learning and predictive modeling to evaluate the immunogenicity of therapeutic...
This is a $92,322 firm fixed-price purchase order awarded by the Food and Drug Administration (FDA) to Proimmune, Inc., a small business contractor, to provide services to the FDA's Center for Biologics Evaluation and Research (CBER), Office of Division of Plasma Protein Therapeutics' (DPPT) / Hemostasis Branch (HB). The contract is for determining a reliable and comprehensive identification of FVIII-derived peptides to compare processing by antigen presenting cells between wild-type and...
This federal contract award was made by the Food and Drug Administration (FDA), a civilian agency, to Qrono, Inc., a for-profit company specializing in medical and scientific research and development. The $694,584.58 cost-plus-fixed-fee contract, titled "Computational Drug Delivery: Leveraging Predictive Models to Develop Bioequivalent Generic Long-Acting Injections," is focused on developing innovative drug delivery systems and immunotherapy approaches. The contract has an ultimate...
This is a $138,210 fixed-price purchase order awarded by the Food and Drug Administration (FDA) to The Emmes Company LLC, a small business based in Rockville, Maryland. The contract is for the "Validation and Qualification of the Modular Immune in vitro Construct (MIMIC)," which supports the FDA's biomedical research efforts. The Emmes Company is an experienced provider of comprehensive services for federal research initiatives, particularly for the National Institutes of Health (NIH)....
This is a $950,450 cost-plus-fixed-fee contract awarded by the Food and Drug Administration (FDA) to CFD Research Corporation, a small business, to develop a Computational Fluid Dynamics (CFD)-Physiologically-Based Pharmacokinetic (PBPK) framework to support the bioequivalence evaluation of ophthalmic drugs. The contract is part of the FDA's Broad Agency Announcement (BAA) for research and development to advance regulatory science and innovation, with no set-aside used. CFD Research...
This federal contract award, valued at $91,000.00, was issued by the National Center for Advancing Translational Sciences (NCATS), which is part of the National Institutes of Health (NIH), a civilian agency. The contract was awarded to Novotech Drug Development Consulting LLC, doing business as CBR International, LLC, a small business. The contract provides regulatory support services for a pre-Investigational New Drug (IND) application meeting with the U.S. Food and Drug Administration (FDA)...
This is a Firm Fixed Price delivery order awarded by the Food and Drug Administration (FDA), a civilian agency, to Eastern Research Group Inc., a for-profit Subchapter S corporation, for a study on "PATIENT EXPERIENCE DATA IN REGULATORY DECISION MAKING." The contract award, valued at $520,205.00, is associated with the FDA's Center for Drug Evaluation and Research (CDER) Priority Analysis indefinite delivery, indefinite quantity (IDIQ) contract vehicle. There is no set-aside...
This is a $5,967,111.25 delivery order contract awarded by the Department of Health and Human Services Food and Drug Administration (FDA) to IQVIA Government Solutions Inc., a provider of healthcare data, analytics, and related services to U.S. federal agencies. The contract was awarded under the FDA's BEST Initiative - Data Tools and Infrastructure for Surveillance of Biologics indefinite delivery, indefinite quantity (IDIQ) contract vehicle. The contract is for the development and...